Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Harbour BioMed Forms Immunotherapy Discovery Collaboration with Moderna

publication date: Nov 11, 2022

Harbour BioMed will use its antibody discovery platform to identify nucleic acid-based oncology immunotherapies for ModernaTX  an RNA company. Moderna will own an exclusive sub-licensable license to exploit a panel of sequences against multiple targets, derived from HBM’s proprietary heavy chain only antibody discovery platform. Moderna will be responsible for all development costs, while Nona Biosciences, an HBM subsidiary, will receive upfront and milestone payments, plus royalties. HBM is headquartered in Boston with discovery operations in Rotterdam and labs in Suzhou. More details....

Stock Symbols: (HK: 02142) (NSDQ: MRNA)

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital